---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-24-000033"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:19:03.919081+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# NovoCure Q3 revenue +22% to $155M; FDA OKs Optune Lua; CEO/CFO transitions set

## Summary
- Q3 net revenues $155.1M (+22% YoY); net loss $30.6M ($0.28 loss per share); adjusted EBITDA $1.7M.
- FDA approved Optune Lua for metastatic NSCLC; Breakthrough Device designation for brain metastases from NSCLC.
- CEO Asaf Danziger retiring Jan 1, 2025; CFO Ashley Cordova to become CEO on that date.
- Christoph Brackmann appointed CFO (from Moderna), effective Jan 1, 2025; compensation disclosed.
- Active patients on therapy 4,113; prescriptions up 8% to 1,586; cash and equivalents $959.9M.

## SEC filing metadata
- accession: 0001645113-24-000033
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000033/0001645113-24-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000033/nvcr-20241029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-24-000033
- JSON: https://secwatch.observer/filing/0001645113-24-000033.json
- Plain text: https://secwatch.observer/filing/0001645113-24-000033.txt

## Key facts
- Executive change
  Christoph Brackmann was appointed as Chief Financial Officer at NovoCure Ltd.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On October 30, 2024, the Company announced the appointment of Christoph Brackmann, age 51, as the Chief Financial Officer of the Novocure Group, effective January 1, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000033/0001645113-24-000033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.